209 related articles for article (PubMed ID: 21114776)
1. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
[TBL] [Abstract][Full Text] [Related]
2. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
Dong M; Xing PY; Liu P; Feng FY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2010 Mar; 32(3):208-11. PubMed ID: 20450590
[TBL] [Abstract][Full Text] [Related]
4. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
5. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
[TBL] [Abstract][Full Text] [Related]
6. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
7. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
8. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
9. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
11. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
Kurniali PC; Luo LG; Weitberg AB
Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Martoni AA; Pinto C; Di Fabio F; Lelli G; Rojas Llimpe FL; Gentile AL; Mutri V; Ballardini P; Giaquinta S; Piana E
Eur J Cancer; 2006 Dec; 42(18):3161-8. PubMed ID: 17098421
[TBL] [Abstract][Full Text] [Related]
13. Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
Wrzesinski SH; McGurk ML; Donovan CT; Ferencz TM; Saif MW
Anticancer Drugs; 2007 Jul; 18(6):721-4. PubMed ID: 17762403
[TBL] [Abstract][Full Text] [Related]
14. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
[TBL] [Abstract][Full Text] [Related]
15. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
[TBL] [Abstract][Full Text] [Related]
16. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
18. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Petrioli R; Paolelli L; Marsili S; Civitelli S; Francini E; Cioppa T; Roviello F; Nettuno R; Intrivici C; Tanzini G; Lorenzi M; Francini G
Oncology; 2006; 70(5):345-50. PubMed ID: 17179728
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
20. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]